Finally, the pleiotropic role of syntaxin-6 across multiple neurodegenerative diseases, including PSP and AD, raises the potential that STX6-targeting therapies could have wider applicability to other neurode-generative diseases, warranting further investigation. This evidence concerns the gene STX6 and supranuclear palsy, progressive, 1.